BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12388926)

  • 1. Serum levels of sTNFR-1 and sFas in patients with relapsing-remitting multiple sclerosis.
    Bilińska M; Frydecka I; Podemski R; Gruszka E
    Med Sci Monit; 2002 Oct; 8(10):CR720-3. PubMed ID: 12388926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Fas antigen on T cell subpopulations in peripheral blood of patients with relapsing-remitting multiple sclerosis.
    Bilińska M; Frydecka I; Podemski R; Teodorowska R; Gruszka E
    Med Sci Monit; 2001; 7(2):251-5. PubMed ID: 11257731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Level of sFas/APO 1 in serum and cerebrospinal fluid in multiple sclerosis.
    Mahovic D; Petravic D; Petelin Z; Zurak N; Horvat G; Hajnsek S
    Clin Neurol Neurosurg; 2004 Jun; 106(3):230-2. PubMed ID: 15177773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis.
    Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Tamborino C; Paolino E; Tola MR; Granieri E; Baricordi OR
    Mult Scler; 2008 May; 14(4):446-54. PubMed ID: 18208868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Estimation and clinical significance of serum soluble tumor necrosis factor receptors in patients with acute leukemia].
    Lin M; Meng X
    Zhonghua Xue Ye Xue Za Zhi; 1999 May; 20(5):245-8. PubMed ID: 11601213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
    Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of iron dysregulation in the pathogenesis of multiple sclerosis: an Egyptian study.
    Abo-Krysha N; Rashed L
    Mult Scler; 2008 Jun; 14(5):602-8. PubMed ID: 18408021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity.
    Frisullo G; Angelucci F; Caggiula M; Nociti V; Iorio R; Patanella AK; Sancricca C; Mirabella M; Tonali PA; Batocchi AP
    J Neurosci Res; 2006 Oct; 84(5):1027-36. PubMed ID: 16865709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis.
    Ysrraelit MC; Gaitán MI; Lopez AS; Correale J
    Neurology; 2008 Dec; 71(24):1948-54. PubMed ID: 19064876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of soluble CD95 are not associated with amelioration of multiple sclerosis during pregnancy.
    Ehrlich S; Haas J; Zipp F; Infante-Duarte C
    J Neurol Sci; 2007 Jan; 252(1):83-7. PubMed ID: 17169375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased serum levels of soluble CD14 indicate stable multiple sclerosis.
    Lutterotti A; Kuenz B; Gredler V; Khalil M; Ehling R; Gneiss C; Egg R; Deisenhammer F; Berger T; Reindl M
    J Neuroimmunol; 2006 Dec; 181(1-2):145-9. PubMed ID: 17046070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocyte activation and disease activity in multiple sclerosis. A longitudinal analysis of serum MRP8/14 levels.
    Floris S; van der Goes A; Killestein J; Knol DL; Barkhof F; Polman CH; Dijkstra CD; de Vries HE; Meilof JF
    J Neuroimmunol; 2004 Mar; 148(1-2):172-7. PubMed ID: 14975598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study.
    Burger RA; Darcy KM; DiSaia PJ; Monk BJ; Grosen EA; Gatanaga T; Granger GA; Wang J; Tian C; Hanjani P; Cohn DE
    Cancer; 2004 Jul; 101(1):106-15. PubMed ID: 15221995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity.
    Sternberg Z; Weinstock-Guttman B; Hojnacki D; Zamboni P; Zivadinov R; Chadha K; Lieberman A; Kazim L; Drake A; Rocco P; Grazioli E; Munschauer F
    Mult Scler; 2008 Jul; 14(6):759-63. PubMed ID: 18505774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with multiple sclerosis have higher levels of serum ghrelin.
    Berilgen MS; Bulut S; Ustundag B; Tekatas A; Ayar A
    Neuro Endocrinol Lett; 2005 Dec; 26(6):819-22. PubMed ID: 16380704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCL11 (Interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone.
    Szczuciński A; Kalinowska A; Losy J
    Eur Neurol; 2007; 58(4):228-32. PubMed ID: 17827967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain excitability changes in the relapsing and remitting phases of multiple sclerosis: a study with transcranial magnetic stimulation.
    Caramia MD; Palmieri MG; Desiato MT; Boffa L; Galizia P; Rossini PM; Centonze D; Bernardi G
    Clin Neurophysiol; 2004 Apr; 115(4):956-65. PubMed ID: 15003779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum IgG and IgM ganglioside GM1 antibodies in patients with multiple sclerosis.
    Zaprianova E; Majtényi K; Deleva D; Mikova O; Filchev A; Sultanov B; Kolyovska V; Sultanov E; Christova L; Kmetska X; Georgiev D
    Ideggyogy Sz; 2004 Mar; 57(3-4):94-9. PubMed ID: 15133910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.
    Hao JH; Ye DQ; Zhang GQ; Liu HH; Dai H; Huang F; Pan FM; Su H; Dong MX; Chen H; Wang Q; Zhang XJ
    Arch Dermatol Res; 2006 Jan; 297(7):329-32. PubMed ID: 16328345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of soluble tumor necrosis factor-p55 levels in the serum and ascitic fluid of patients with hepatocellular carcinoma.
    Gao L; Bai L; Nan QZ; Yang XS; Chen K; Wen HP; Lai ZS; Bo L; Zhang YL; Zhang ZS
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Jul; 22(7):641-3. PubMed ID: 12376300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.